TOPIC

BIOTECH News & Analysis

Share plunge presents undervalued opportunity for well-known ASX blue chip
Stocks
Share plunge presents undervalued opportunity for well-known ASX blue chip
Shares in this well-known ASX20 stock have tumbled in recent weeks, but is the market selloff overdone?  
Joshua Peach | 11 July 2023
CSL's first-half challenged by covid-19 restrictions
Stocks
CSL's first-half challenged by covid-19 restrictions
First-half group net profit was driven lower by higher plasma collection costs.
Shane Ponraj | 18 February 2022
How do fund managers approach boom-or-bust biotech stocks?
Stocks
How do fund managers approach boom-or-bust biotech stocks?
Benchmark rebalance in June put pressure on some small-cap managers to get into the sector.
29 November 2021
Chinese biotech: Buy the dip?
Stocks
Chinese biotech: Buy the dip?
Morningstar looks at two diversified Chinese biotech names.
Kate Lin | 07 September 2021
Biotech beyond covid
Video
Biotech beyond covid
Are there still opportunities in the biotech sector now the covid-19 vaccine roll out is underway? We ask International Biotechnology Trust manager...
Holly Black | 22 June 2021
Avita still undervalued despite downgrade
Stocks
Avita still undervalued despite downgrade
The single-product company is high-risk, high-reward.
Lewis Jackson | 25 May 2021
Waiving vaccine IP doesn't affect market assessment: Morningstar
Stocks
Waiving vaccine IP doesn't affect market assessment: Morningstar
We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.
Karen Andersen, CFA | 07 May 2021
Should you invest in the vaccine makers?
Stocks
Should you invest in the vaccine makers?
Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.
Morningstar.com.au | 19 January 2021
10 cheap innovative stocks
Stocks
10 cheap innovative stocks
These names from the Morningstar Exponential Technologies Index are trading at 4-star levels.
Susan Dziubinski | 18 June 2020
4 healthcare stocks attractive on valuation and ESG risk
Video
4 healthcare stocks attractive on valuation and ESG risk
Morningstar's Karen Andersen explains how environmental, social and governance issues affect Big Pharma and biotech companies.
Karen Andersen, CFA | 10 February 2020